Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024-2033

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $12.84 billion In 2028 At A CAGR Of 7.4% :

The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to aging population, prevalence of diabetes, awareness and early diagnosis, global initiatives in eye health, pharmaceutical innovations, patient advocacy and support..

The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $12.84 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine approaches, rising awareness in emerging markets, focus on combination therapies, integration with teleophthalmology services, global aging demographics.. Major trends in the forecast period include advancements in sustained-release drug delivery, integration of gene therapies, development of novel imaging technologies, personalized treatment approaches based on biomarkers, teleophthalmology for remote monitoring, advancements in artificial intelligence for diagnostics..

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp

Macular Edema and Macular Degeneration Market Major Segments

The macular edema and macular degeneration market covered in this report is segmented -

1) By Treatment Type: Drug Therapy, Laser Treatment
2) By Application: Macular Edema, Diabetic Macular Edema (DME), Cystoid Macular Edema (CME), Macular Degeneration, Dry age-related macular degeneration, Wet age-related macular degeneration
3) By End User: Hospitals, Clinics, Other End Users

Key Driver - Elevated Diabetes Prevalence Fuels Growth In The Macular Edema And Macular Degeneration Market

The rising diabetes population is expected to propel the growth of the macular edema and macular degeneration market going forward. Diabetes is a chronic medical condition characterized by high glucose (sugar) levels in the blood. Diabetes damages the blood vessels in the eye, which can result in macular edema and macular degeneration. For instance, in April 2023, according to a report published by The British Diabetic Association, a UK-based diabetes charity, the number of people living with diabetes has reached an all-time high of over 5 million, with 4.3 million people diagnosed with diabetes and an estimated 850,000 people living with the condition but not yet diagnosed. Further, more than 2.4 million people in the UK are at high risk of developing type 2 diabetes, and registration numbers for 2021-22 are up by 148,951 from 2020-21. Therefore, the rising diabetes population is driving the growth of the macular edema and macular degeneration market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=13479&type=smp

Prominent Trend - Innovative Medication Advancements In The Macular Edema And Macular Degeneration Market

Major companies operating in the macular edema and macular degeneration market are focusing on developing innovative products such as Vabysmo (faricimab-svoa) to increase their profitability in the market. Vabysmo (faricimab-svoa) is a medication used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). For instance, in January 2022, Genentech Inc., a US-based biotechnology corporation, got Vabysmo (faricimab-svoa) approval from the Food and Drug Administration. It is a bispecific antibody that targets vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), making it the first bispecific monoclonal antibody for both disorders. Faricimab has the potential to become a blockbuster medication for the treatment of nAMD and DME, and the FDA and EU approval of it has been a significant milestone for Genentech and Roche.

Macular Edema and Macular Degeneration Market Players
Major companies operating in the macular edema and macular degeneration market report are F. Hoffmann La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Bausch Health Companies Inc., Clover Therapeutics Inc., Santen Pharmaceutical Co. Ltd., Samsung Bioepis Inc., PanOptica Inc., Regen X Bio Inc., Aerie Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd., Alimera Sciences Inc., Kodiak Sciences Inc., Acucela Inc., Editas Medicine Inc., IVERIC bio Inc., Lineage Cell Therapeutics Inc., Allegro Ophthalmics Ltd., Ampio Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Graybug Vision Inc., Clearside Biomedical Inc., Ocugen Inc., Opthea Limited

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the macular edema and macular degeneration market market in 2023. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Macular Edema and Macular Degeneration Market Report Structure
3. Macular Edema and Macular Degeneration Market Trends And Strategies
4. Macular Edema and Macular Degeneration Market - Macro Economic Scenario
5. Macular Edema and Macular Degeneration Market Size And Growth
…..
27. Macular Edema and Macular Degeneration Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.